Drug Profile
ERY 974
Alternative Names: ERY-974; T cell redirecting bispecific antibody - ChugaiLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Solid tumours
- Preclinical Gastric cancer
Most Recent Events
- 25 Apr 2022 Phase-I development is ongoing in Solid tumours (Late-stage disease) in USA, France, Netherlands (IV, Injection)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in France (IV, Injection)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Netherlands (IV, Injection)